

Libtayo® (cemiplimab-rwlc) (Intravenous)

-E-

Document Number: IC-0473

Date Approved: 05/05/2025

Date of Origin: 07/01/2019

Dates Reviewed: 07/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021, 10/2021, 02/2022, 05/2022, 07/2022, 10/2022, 01/2023, 04/2023, 07/2023, 10/2023, 01/2024, 04/2024, 08/2024, 11/2024, 01/2025, 04/2025

I. Length of Authorization ^{Δ 1,12,14}

Coverage will be provided for 6 months and may be renewed, unless otherwise specified.

- Neoadjuvant therapy in Cutaneous Squamous Cell Carcinoma (cSCC) can be authorized up to a maximum of 4 doses and cannot be renewed.
- Treatment for metastatic, locally advanced, or recurrent cSCC, and Basal Cell Carcinoma (BCC) can be renewed up to a maximum of twenty-four (24) months of therapy (35 doses).
- Treatment for Cervical Cancer, Vaginal Cancer and Vulvar Cancer can be authorized up to a maximum of ninety-six (96) weeks of therapy (32 doses).

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 350 billable units (350 mg) every 21 days

III. Initial Approval Criteria ¹

Coverage is provided for the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy, unless otherwise specified ^Δ; **AND**

Cutaneous Squamous Cell Carcinoma (cSCC) † ‡ ^{1-5,8,12}

- Used as a single agent; **AND**
 - Patient has metastatic, locally advanced, or recurrent disease ^Δ; **AND**
 - Patient is not a candidate for curative surgery or curative radiation therapy; **OR**

- Used as neoadjuvant therapy; **AND**
 - Patient has borderline resectable disease, unresectable disease **Ω**, or surgery may carry a high morbidity; **OR**
 - Used for one of the following:
 - Tumor has very rapid growth
 - In-transit metastasis
 - Lymphovascular invasion
 - Surgery alone may not be curative or may result in significant functional limitation; **AND**
 - Patient has very high-risk disease*; **OR**
 - Patient has locally advanced disease

** Very High-Risk features include preoperative clinical tumor diameter >4 cm, poor differentiation, desmoplastic disease, thickness or level of invasion is >6 mm or invasion beyond subcutaneous fat, tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring ≥0.1 mm, lymphatic or vascular involvement*

Cervical Cancer ‡^{2,14,7e}

- Used as a single agent as subsequent therapy; **AND**
- Patient has recurrent or metastatic disease **Δ**; **AND**
- Patient has received a prior platinum-based chemotherapy regimen, unless contraindicated

Basal Cell Carcinoma (BCC) † ‡^{1,2,6,9,13}

- Patient has previously been treated with a hedgehog pathway inhibitor (HHI) (e.g., vismodegib, sonidegib, etc.) or for whom HHI treatment is not appropriate; **AND**
- Used as a single agent; **AND**
 - Patient has locally advanced or metastatic disease **Δ**; **OR**
 - Patient has nodal disease and surgery is not feasible **Δ**

Non-Small Cell Lung Cancer (NSCLC) † ‡^{1,2,7,10,15,16}

- Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease with no evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
 - Used in combination with platinum-based chemotherapy (e.g., paclitaxel and either carboplatin or cisplatin OR pemetrexed and either carboplatin or cisplatin); **AND**
 - Used as first-line therapy for one of the following:
 - Patients who have tumors that are negative for actionable molecular biomarkers* **¥**
 - Patients who are positive for one of the following molecular biomarkers: EGFR exon 20, BRAF V600E, NTRK1/2/3 gene fusion, MET exon 14 skipping, NRG1 gene fusion, or ERBB2 (HER2); **OR**

- Used as subsequent therapy for one of the following:
 - Patients who are positive for one of the following molecular biomarkers and have received prior targeted therapy§: EGFR S768I, L861Q, and/or G719X
 - Patients who are positive for one of the following molecular biomarkers: BRAF V600E, NTRK1/2/3 gene fusion or MET exon 14 skipping; **OR**
- Used in combination with pemetrexed; **AND**
 - Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease after first-line therapy with cemiplimab, pemetrexed, and either carboplatin or cisplatin for non-squamous cell histology; **OR**
- Used as a single agent; **AND**
 - Patient has tumors that are negative for actionable molecular biomarkers* ¶ and high PD-L1 expression (Tumor Proportion Score [TPS] ≥ 50%) as determined by an FDA-approved or CLIA compliant test❖; **AND**
 - Used as first-line therapy †; **OR**
 - Used as continuation maintenance therapy in patients who achieved a tumor response or stable disease after first-line therapy with cemiplimab as monotherapy or as part of combination therapy; **OR**
 - Patient has tumors with PD-L1 expression <1% or ≥1%-49%; **AND**
 - Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy with cemiplimab combination therapy

** Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, and ERBB2 (HER2). Complete genotyping for EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1 and ERBB2 (HER2), via biopsy and/or plasma testing. If a clinically actionable marker is found, it is reasonable to start therapy based on the identified marker. Treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

¶ Note: May also be used for patients with KRAS G12C mutation positive tumors.

§ Note: Genomic Aberration/Mutational Driver Targeted Therapies: Refer to guidelines for appropriate use

Small Bowel Adenocarcinoma ‡ Ω^{2,17}

- Used as single agent treatment; **AND**
- Patient has microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) disease OR polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype [e.g., tumor mutational burden (TMB) > 50 mut/Mb] as determined by an FDA-approved or CLIA-compliant test❖; **AND**
 - Patient has advanced or metastatic disease; **AND**
 - Used as primary treatment; **OR**

- Used as subsequent treatment for POLE/POLD1 mutation ONLY (excluded for MSI-H/dMMR); **OR**
- Patient has locally unresectable or medically inoperable disease; **AND**
 - Used as primary treatment

Vaginal Cancer ± Ω^{2,14}

- Used as a single agent as subsequent therapy; **AND**
- Patient has recurrent or metastatic disease ^Δ; **AND**
- Patient has received a prior platinum-based chemotherapy regimen, unless contraindicated

Vulvar Cancer ± Ω^{2,4,14}

- Used as a single agent as subsequent therapy; **AND**
- Patient has advanced or recurrent/metastatic disease ^Δ; **AND**
- Patient has received a prior platinum-based chemotherapy regimen, unless contraindicated

Colon Cancer ± Ω^{2,19}

- Used as single agent treatment; **AND**
- Patient has POLE/POLD1 mutation Ω with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) as determined by an FDA-approved or CLIA-compliant test ♦; **AND**
- Used for locally unresectable, medically inoperable, advanced, or metastatic disease

Appendiceal Adenocarcinoma – Colon Cancer ± Ω^{2,19}

- Used as single agent treatment; **AND**
- Patient has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) as determined by an FDA-approved or CLIA-compliant test ♦; **AND**
- Patient has advanced or metastatic disease

Rectal Cancer ± Ω^{2,20}

- Used as single agent treatment; **AND**
- Patient has POLE/POLD1 mutation Ω with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) as determined by an FDA-approved or CLIA-compliant test ♦; **AND**
- Used for advanced or metastatic disease

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.

❖ If confirmed using an FDA approved assay – <http://www.fda.gov/companiondiagnostics>

Ω Please note that the supporting data for this indication has been assessed and deemed to be of insufficient quality based on the review conducted for the Enhanced Oncology Value (EOV) program. However, due to the absence of viable alternative treatment options, this indication will be retained in our policy and evaluated on a case-by-case basis.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria ^{Δ 1,12}

Coverage may be renewed based on the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Duration of authorization has not been exceeded (*refer to Section I*); **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion-related reactions, severe and fatal immune-mediated adverse reactions (e.g., pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatological adverse reactions, etc.), complications of allogeneic hematopoietic stem cell transplantation (HSCT), etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread

^Δ **Notes:**

- Patients responding to therapy who relapse ≥ 6 months after discontinuation due to duration are eligible to re-initiate PD-directed therapy.
- Patients previously presenting with aggressive disease who are exhibiting stable disease on treatment as their best response (or if therapy improved performance status) may be eligible for continued therapy without interruption or discontinuation.
- Patients who complete adjuvant therapy and progress ≥ 6 months after discontinuation are eligible to re-initiate PD-directed therapy for metastatic disease.
- Patients whose tumors, upon re-biopsy, demonstrate a change in actionable mutation (e.g., MSS initial biopsy; MSI-H subsequent biopsy) may be eligible to re-initiate PD-directed therapy and will be evaluated on a case-by-case basis.

V. Dosage/Administration ^{Δ 1,12,14,17-21}

Indication	Dose
cSCC	<u>Metastatic, locally advanced, or recurrent disease:</u>

	Administer 350 mg intravenously every 3 weeks for up to a maximum of 24 months in patients without disease progression or unacceptable toxicity <u>Neoadjuvant therapy:</u> Administer 350 mg intravenously every 3 weeks for up to 4 doses in patients without disease progression or unacceptable toxicity
Cervical Cancer, Vaginal Cancer, and Vulvar Cancer	Administer 350 mg intravenously every 3 weeks up to a maximum of 96 weeks in patients without disease progression or unacceptable toxicity
BCC	Administer 350 mg intravenously every 3 weeks up to a maximum of 24 months in patients without disease progression or unacceptable toxicity
NSCLC, Small Bowel Adenocarcinoma, Anal Carcinoma, Colon Cancer, Rectal Cancer, and Appendiceal Adenocarcinoma	Administer 350 mg intravenously every 3 weeks until disease progression or unacceptable toxicity.

VI. Billing Code/Availability Information

HCPCS Code:

- J9119 – Injection, cemiplimab-rwlc, 1 mg; 1 billable units = 1 mg

NDC:

- Libtayo 350 mg/7 mL single-dose vial: 61755-0008-xx

VII. References (STANDARD)

1. Libtayo [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; April 2024. Accessed April 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) cemiplimab-rwlc. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
3. Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016.
4. Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.
5. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.

6. Lewis KD, Fury MG, Stankevich, et al. Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy. *Annals of Oncology*. 2018 Oct 01; Volume 29, Supplement 8,VII440.
7. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet*. 2021 Feb 13;397(10274):592-604.
8. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Squamous Cell Skin Cancer. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025
9. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Basal Cell Skin Cancer. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
10. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Non-Small Cell Lung Cancer. Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
11. Gogishvili M, Melkadze T, Makharadze T, et al. LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). *Annals of Oncology*, ISSN: 0923-7534, Vol: 32, SUPPLEMENT 5, S1328, SEPTEMBER 01, 2021. DOI10.1016/j.annonc.2021.08.2130.
12. Gross N, Miller D, Khushalani N, et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma *N Engl J Med* 2022; 387:1557-1568. doi: 10.1056/NEJMoa2209813
13. Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2021;22:848-857.
14. Tewari KS, Monk BJ, Vergote I, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med* 2022;386:544-555.
15. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. *Nat Med*. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25. PMID: 36008722; PMCID: PMC9671806.

16. Özgüroğlu M, Kilickap S, Sezer A, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2023; 24: 989–1001.
17. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Small Bowel Adenocarcinoma. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
18. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Anal Carcinoma. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
19. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Colon Cancer. Version 1.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
20. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Rectal Cancer. Version 1.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
21. Paccaly AJ, Migden MR, Papadopoulos KP, et al. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. *Adv Ther* 2021;38:2365-2378.

VIII. References (ENHANCED)

- 1e. Maubec E1, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. *J Clin Oncol*. 2011 Sep 1;29(25):3419-26. doi: 10.1200/JCO.2010.34.1735. Epub 2011 Aug 1.
- 2e. Jarkowski A 3rd, Hare R, Loud P, et al. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. *Am J Clin Oncol*. 2016 Dec;39(6):545-548.

- 3e. Lu SM, Lien WW. Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. *Am J Clin Oncol*. 2018 Jan;41(1):95-99.
- 4e. Grob J, Gonzalez Mendoza R, Basset-Seguin N, et al. Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. *Ann Oncol*. 2019;30(suppl_5):v908. doi: 10.1093/annonc/mdz394.069.
- 5e. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.
- 6e. Spigel DR, De Marinis F, Giaccone G, et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC [abstract]. *Ann Oncol* 2019;30(suppl_5):Abstract 6256.
- 7e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Cervical Cancer. Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
- 8e. Coleman RL, Lorusso D, Gennigens C, et al; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9.
- 9e. Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2019 Jun 10;37(17):1470-1478. Doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.
- 10e. Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. *Journal for ImmunoTherapy of Cancer*. 2021;9(8):e002757. doi:<https://doi.org/10.1136/jitc-2021-002757>
- 11e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Vaginal Cancer. Version 5.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2025.
- 12e. Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTCGCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). *Ann Oncol* 2009;20:1511-1516.

- 13e.Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol.* 2017 Apr;18(4):446-453.
- 14e.Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. *Ann Oncol.* 2017 May 1;28(5):1036-1041.
- 15e.Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. *Lancet Gastroenterol Hepatol.* 2022 May;7(5):446-454. doi: 10.1016/S2468-1253(21)00382-4. Epub 2022 Feb 1. PMID: 35114169.
- 16e.Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). *ESMO Open.* 2022 Aug;7(4):100529.
- 17e.Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. *Journal of Clinical Oncology.* 2019;37(15_suppl):3521-3521. doi:https://doi.org/10.1200/jco.2019.37.15_suppl.3521
- 18e.André Thewis, Élez E, Éric Van Cutsem, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. *Journal of Clinical Oncology.* 2024;42(3_suppl):LBA768-LBA768. doi:https://doi.org/10.1200/jco.2024.42.3_suppl.lba768
- 19e.Andre T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. *Journal of Clinical Oncology.* 2020;38(18_suppl):LBA4-LBA4. doi:https://doi.org/10.1200/jco.2020.38.18_suppl.lba4
- 20e.Lakhani N, Cosman R, Banerji U, et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101). *ESMO Open.* 2024;9(4):102254-102254. doi:https://doi.org/10.1016/j.esmoop.2024.102254
- 21e.Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *The Lancet Oncology.* 2017;18(9):1182-1191. doi:https://doi.org/10.1016/S1470-2045(17)30422-9
- 22e.Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine.* 2015;372(26):2509-2520. doi:https://doi.org/10.1056/nejmoa1500596
- 23e.Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164. *Journal of Clinical Oncology.* 2020;38(1):11-19. doi:https://doi.org/10.1200/jco.19.02107

- 24e. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. *Journal of Clinical Oncology*. 2021;39(15_suppl):2564-2564. doi:https://doi.org/10.1200/jco.2021.39.15_suppl.2564
- 25e. Li J, Xu Y, Zang A, et al. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors. *PubMed*. 2024;36(3):257-269. doi:https://doi.org/10.21147/j.issn.1000-9604.2024.03.03
- 26e. Chalabi M, Verschoor YL, Pedro Batista Tan, et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. *New England journal of medicine/The ðNew England journal of medicine*. 2024;390(21):1949-1958. doi:https://doi.org/10.1056/nejmoa2400634
- 27e. Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. *New England Journal of Medicine*. 2022;386(25). doi:https://doi.org/10.1056/nejmoa2201445
- 28e. Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. Published online January 9, 2023;JCO2201351. doi:https://doi.org/10.1200/JCO.22.01351
- 29e. Prime Therapeutics Management. Libtayo Clinical Literature Review Analysis. Last updated April 2025. Accessed April 2025.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified

ICD-10	ICD-10 Description
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C44.01	Basal cell carcinoma of skin of lip
C44.02	Squamous cell carcinoma of skin of lip
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus
C44.1121	Basal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122	Basal cell carcinoma of skin of right lower eyelid, including canthus
C44.1191	Basal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192	Basal cell carcinoma of skin of left lower eyelid, including canthus
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus
C44.1221	Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1222	Squamous cell carcinoma of skin of right lower eyelid, including canthus
C44.1291	Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292	Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal

ICD-10	ICD-10 Description
C44.310	Basal cell carcinoma of skin of unspecified parts of face
C44.311	Basal cell carcinoma of skin of nose
C44.319	Basal cell carcinoma of skin of other parts of face
C44.320	Squamous cell carcinoma of skin of unspecified parts of face
C44.321	Squamous cell carcinoma of skin of nose
C44.329	Squamous cell carcinoma of skin of other parts of face
C44.41	Basal cell carcinoma of skin of scalp and neck
C44.42	Squamous cell carcinoma of skin of scalp and neck
C44.510	Basal cell carcinoma of anal skin
C44.511	Basal cell carcinoma of skin of breast
C44.519	Basal cell carcinoma of skin of other part of trunk
C44.520	Squamous cell carcinoma of anal skin
C44.521	Squamous cell carcinoma of skin of breast
C44.529	Squamous cell carcinoma of skin of other part of trunk
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712	Basal cell carcinoma of skin of right lower limb, including hip
C44.719	Basal cell carcinoma of skin of left lower limb, including hip
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip
C44.81	Basal cell carcinoma of overlapping sites of skin
C44.82	Squamous cell carcinoma of overlapping sites of skin
C44.91	Basal cell carcinoma of skin, unspecified
C44.92	Squamous cell carcinoma of skin, unspecified
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C51.9	Malignant neoplasm of vulva, unspecified
C52	Malignant neoplasm of vagina
C53.0	Malignant neoplasm of endocervix

ICD-10	ICD-10 Description
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
Z85.068	Personal history of other malignant neoplasm of small intestine
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
15	KY, OH	CGS Administrators, LLC